quinazolines has been researched along with Neurofibromatosis 2 in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 8 (88.89) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abbadi, S; Blakeley, JO; Bonne, N; Brem, H; Giovannini, M; Itzoe, M; Paldor, I; Rodriguez, FJ; Rowshanshad, D; Tyler, BM; Vigilar, V; Ye, X | 1 |
| Allen, JC; Hagiwara, M; Hu, J; Karajannis, MA; Mitchell, C; Osorio, DS; Stanek, J | 1 |
| Ardern-Holmes, S; de Souza, P; Lim, SH; McCowage, G | 1 |
| Halpin, C; Harris, GJ; McClatchey, AI; O'Donnell, CC; Plotkin, SR; Singh, MA | 1 |
| Chan, AW; di Tomaso, E; Jain, RK; Kamoun, WS; Lahdenranta, J; McClatchey, AI; Plotkin, SR; Wong, HK | 1 |
| Barker, FG; Batchelor, TT; Halpin, C; Loeffler, JS; McKenna, MJ; Plotkin, SR | 1 |
| Hamilton, J; Hong, DS; Ketonen, LM; Kurzrock, R; McCutcheon, IE; Slopis, J; Subbiah, V | 1 |
| Plotkin, SR; Terry, AR | 1 |
| Allen, JC; Ballas, MS; Brown, K; Goldberg, JD; Golfinos, JG; Hagiwara, M; Hochman, T; Karajannis, MA; Koch, KM; Legault, G; Nusbaum, AO; Roland, JT | 1 |
2 review(s) available for quinazolines and Neurofibromatosis 2
| Article | Year |
|---|---|
Systemic therapy in neurofibromatosis type 2.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Clinical Trials as Topic; ErbB Receptors; Humans; Lapatinib; Molecular Targeted Therapy; Neurofibromatosis 2; Quinazolines; Signal Transduction | 2014 |
Chemotherapy: present and future.
Topics: Antibodies, Monoclonal, Humanized; Bevacizumab; Clinical Trials, Phase II as Topic; ErbB Receptors; Erlotinib Hydrochloride; Evidence-Based Medicine; Female; Follow-Up Studies; Forecasting; Humans; Magnetic Resonance Imaging; Male; Molecular Targeted Therapy; Neurofibromatosis 2; Neuroma, Acoustic; Quinazolines; Radiosurgery; Risk Assessment; Treatment Outcome | 2012 |
3 trial(s) available for quinazolines and Neurofibromatosis 2
| Article | Year |
|---|---|
Effect of lapatinib on meningioma growth in adults with neurofibromatosis type 2.
Topics: Adult; Antineoplastic Agents; Female; Humans; Imaging, Three-Dimensional; Lapatinib; Magnetic Resonance Imaging; Male; Meningeal Neoplasms; Meningioma; Middle Aged; Neurofibromatosis 2; Neuroma, Acoustic; Quinazolines; Retrospective Studies; Young Adult | 2018 |
Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Child; Child, Preschool; Drug Synergism; Erlotinib Hydrochloride; Female; Humans; Indoles; Male; Molecular Targeted Therapy; Neurofibromatosis 2; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Treatment Outcome; Valproic Acid; Vascular Endothelial Growth Factor A; Young Adult | 2012 |
Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Lapatinib; Magnetic Resonance Imaging; Male; Middle Aged; Neurofibromatosis 2; Neuroma, Acoustic; Prognosis; Prospective Studies; Quinazolines; Survival Rate; Tissue Distribution; Young Adult | 2012 |
4 other study(ies) available for quinazolines and Neurofibromatosis 2
| Article | Year |
|---|---|
The efficacy of lapatinib and nilotinib in combination with radiation therapy in a model of NF2 associated peripheral schwannoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cell Line, Tumor; Cell Survival; Chemoradiotherapy; Everolimus; Lapatinib; Mice; Mice, Nude; Mice, Transgenic; Models, Statistical; Neoplasm Transplantation; Neurilemmoma; Neurofibromatosis 2; Peripheral Nervous System Neoplasms; Pyrimidines; Quinazolines; Sciatic Nerve; Time Factors | 2017 |
Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy.
Topics: Audiometry, Pure-Tone; Auditory Threshold; Cochlear Implantation; Combined Modality Therapy; Ear Neoplasms; Erlotinib Hydrochloride; Hearing Loss, Sensorineural; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neurofibromatosis 2; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; Vestibular Diseases | 2008 |
Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Cell Growth Processes; Cell Line, Tumor; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; Neurilemmoma; Neurofibromatosis 2; Neurofibromin 2; Piperidines; Quinazolines; Vascular Endothelial Growth Factor A | 2010 |
Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients.
Topics: Adolescent; Adult; Antineoplastic Agents; Audiometry, Pure-Tone; Disease Progression; Erlotinib Hydrochloride; Female; Hearing Loss, Sensorineural; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neurofibromatosis 2; Neuroma, Acoustic; Quinazolines; Speech Perception; Treatment Outcome; Young Adult | 2010 |